2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

702. CAR-T Cell Therapies: Basic and Translational: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Cell Expansion, Computational Biology, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Gene Therapy, Immunotherapy, Non-Biological Therapies, Radiation Therapy, Adverse Events, Artificial Intelligence (AI), Deep Learning, Biological Processes, Genomics, Hematopoiesis, Immune Mechanism, Microbiome, Molecular Biology, Diseases, Immunology, Autoimmune Disorders, Immunodeficiency, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, AML, Translational Research, CML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Study Population, Human, Adult, Elderly, Young Adult, Animal Model
PAPER

5890 Chemo-resistant mature polymorphonuclear immunosuppressive myeloid cells (PMN-MDSC) predict CAR-T failure in large B-cell lymphoma

Eugenio Galli, Alessandra Battaglia2, Andrea Fattorossi3, Ilaria Pansini4, Marco Fossati5, Alessandro Corrente6, Giacomo Di Cesare7, Elena Maiolo8, Silvia Bellesi, MD9, Stefan Hohaus10, Patrizia Chiusolo, MD11, Simona Sica, MD, PhD12, Federica SORA, MD, PhD, MBBS13
1 Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Lazio, Italy
2 Università Cattolica del Sacro Cuore, Rome, Italy
3 Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
4 Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Lazio, Italy
5 Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
6 Università Cattolica del Sacro Cuore, Rome, Italy
7 Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Lazio, Italy
8 Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Lazio, Italy
9 Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Lazio, Italy
10 Università Cattolica del Sacro Cuore, Rome, Italy
11 Università Cattolica del Sacro Cuore, Rome, Italy
12 Università Cattolica del Sacro Cuore, Rome, Italy
13 Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Lazio, Italy

Background. Despite the remarkable efficacy of CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy, primary resistance remains a major cause of treatment failure in relapsed/refractory large B-cell lymphoma (R/R LBCL). Myeloid-derived suppressor cells (MDSCs) are key mediators of tumor-induced immune suppression and have been implicated in resistance to cancer immunotherapy; however, their role in CAR-T therapy remains poorly characterized. We prospectively evaluated the clinical and biological impact of circulating monocytic (Mo-MDSCs) and polymorphonuclear MDSC (PMN-MDSC) subsets in patients with R/R LBCL treated with commercial CD19-directed CAR-T cells.

Methods. Ninety-eight consecutive patients receiving commercial CD19-directed CAR-T therapy were prospectively enrolled. Peripheral blood samples were collected before lymphodepletion (day −5) and immediately before CAR-T infusion (day 0). Mo-MDSCs (CD45+CD14+HLA-DR^neg) and immature/mature PMN-MDSCs (CD45^dim/+CD15+LOX-1+) were quantified by multiparameter flow cytometry directly in whole blood. PMN-MDSC suppressive activity was confirmed in vitro using T-cell proliferation assays. Associations with inflammatory markers, CAR-T expansion, clinical response, progression-free survival (PFS), and immune-related toxicities were evaluated using univariable and multivariable models.

Results. Baseline PMN-MDSC levels were associated with systemic inflammation, including CRP, ferritin, serum amyloid A, InflaMix status, and elevated LDH, whereas Mo-MDSCs showed weaker associations with inflammatory biomarkers. Both immature and mature PMN-MDSCs demonstrated potent suppression of T-cell proliferation in vitro, confirming their immunosuppressive function. Following fludarabine/cyclophosphamide lymphodepletion, immature PMN-MDSCs and Mo-MDSCs significantly decreased, whereas mature PMN-MDSCs were largely preserved, suggesting relative resistance to standard conditioning chemotherapy. Elevated mature PMN-MDSC levels at both day −5 and day 0 were associated with a significantly lower probability of achieving response at month 1 (OR=3.75 and OR=2.60, respectively; both P<0.001) and month 3 (OR=2.16, P=0.002; OR=1.57, P=0.047). Similar associations were observed for immature PMN-MDSCs and Mo-MDSCs. Higher mature PMN-MDSC percentages at day 0 were also associated with inferior PFS (HR=1.09, P=0.022). In multivariable analysis including LDH, disease stage and systemic inflammatory status, mature PMN-MDSCs remained independently associated with failure to achieve response at month 3 (OR=1.68, P=0.032). MDSC levels were not associated with quantitative CAR-T expansion. Exploratory analyses identified associations between higher PMN-MDSC levels and increased CD4/CD8 ratios among circulating CAR-T cells, while elevated Mo-MDSCs were associated with a higher proportion of TEMRA-differentiated CAR-T cells. Higher mature PMN-MDSC and Mo-MDSC levels were also associated with increased risk of grade ≥2 cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, corticosteroid use, and intensive care admission.

Conclusions. Mature PMN-MDSCs identify a previously underrecognized mechanism of primary resistance to CD19-directed CAR-T therapy in LBCL. Their persistence despite standard lymphodepleting chemotherapy and their independent association with inferior early response beyond tumor burden and systemic inflammation support their role as clinically relevant biomarkers of CAR-T efficacy. Despite their potent immunosuppressive activity, the expansion of MDSCs was not associated with any attenuation of either baseline tumor-associated inflammation or CAR-T-related inflammatory toxicity, suggesting a functional dissociation between suppression of antitumor immunity and regulation of systemic inflammatory responses. These findings provide a strong rationale for therapeutic strategies aimed at targeting myeloid immunosuppression before CAR-T infusion to improve clinical outcomes.

Eugenio Galli: No relevant conflicts of interest to declare.